Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10716993 | 0.87 | TSHR (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4HDAC1 | |
| SCHEMBL25840464 | 0.80 | CA12 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4HDAC1 | |
| SCHEMBL10643661 | 0.73 | TSHR (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4HDAC1 | |
| SCHEMBL11599452 | 0.72 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12514257 | 0.71 | CA12 (0.43) | HDAC1HDAC6TSHR | |
| SCHEMBL9303490 | 0.71 | TSHR (0.42) | HDAC1HDAC6TSHR | |
| SCHEMBL6872052 | 0.71 | CHRNB2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL22861460 | 0.70 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4TSHR | |
| SCHEMBL12701851 | 0.70 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4TSHR | |
| SCHEMBL11871517 | 0.68 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | EVOTEC (FRANCE) SAS (FR) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | CHRNB2 4814/4885CHRNB4 4831/4885CHRNA3 4838/4885 |
| US-20230013344-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | CHRNB2 4814/4885CHRNB4 4831/4885CHRNA3 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.